SHSE:600613's EV-to-FCF is ranked better than 74.6% of 563
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs SHSE:600613: 11.34
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Shenqi Pharmaceutical Investment Management Co's PE Ratio (TTM) for today is calculated as:
Shanghai Shenqi Pharmaceutical Investment Management Co's share price for today is ¥4.82.
Shanghai Shenqi Pharmaceutical Investment Management Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Shanghai Shenqi Pharmaceutical Investment Management Co EV-to-FCF Related Terms
Shanghai Shenqi Pharmaceutical Investment Management Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Shenqi Pharmaceutical Investment Management Co EV-to-FCF Chart
Shanghai Shenqi Pharmaceutical Investment Management Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Shenqi Pharmaceutical Investment Management Co EV-to-FCF vs Drug Manufacturers Industry
Shanghai Shenqi Pharmaceutical Investment Management Co's current Enterprise Value is ¥1,921 Mil.
Shanghai Shenqi Pharmaceutical Investment Management Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥169 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) has a EV-to-FCF of 11.34 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors. This is 40% below median its historical median of 18.91. According to the industry distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #143 out of 563 companies in the Drug Manufacturers industry, placing it in the top 25.4%.
Is Shanghai Shenqi Pharmaceutical Investment Management Co's EV-to-FCF too high?
Shanghai Shenqi Pharmaceutical Investment Management Co's current EV-to-FCF of 11.34 is 40% below median its 10-year median of 18.91. The Drug Manufacturers industry median EV-to-FCF is 20.85. Shanghai Shenqi Pharmaceutical Investment Management Co's value of 11.34 is 45.6% below this industry median. Based on the distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #143 out of 563 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shanghai Shenqi Pharmaceutical Investment Management Co has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Shenqi Pharmaceutical Investment Management Co's EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #143 out of 563 companies for EV-to-FCF. This puts Shanghai Shenqi Pharmaceutical Investment Management Co in the upper half of its industry. The industry median EV-to-FCF is 20.85. Shanghai Shenqi Pharmaceutical Investment Management Co's value of 11.34 is 45.6% below this benchmark. While the company's 10-year median is 18.91 vs. the industry median of 20.85, Shanghai Shenqi Pharmaceutical Investment Management Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Shenqi Pharmaceutical Investment Management Co's current EV-to-FCF of 11.34 is 45.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Shenqi Pharmaceutical Investment Management Co's current EV-to-FCF is 11.34, which is 40% below median its own 10-year median of 18.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Shenqi Pharmaceutical Investment Management Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.44, compared to a current price of ¥4.82 — trading 11.4% below its estimated fair value. The current EV-to-FCF is 11.34, which is 40% below median its 10-year median of 18.91 and 45.6% below the Drug Manufacturers industry median of 20.85. Shanghai Shenqi Pharmaceutical Investment Management Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613), the current EV-to-FCF is 11.34 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co stock appears to be undervalued.
The current stock price of ¥4.82 is trading 11.4% below its estimated GF Value™ of ¥5.44.
GuruFocus considers Shanghai Shenqi Pharmaceutical Investment Management Co to be Modestly Undervalued.
Key valuation signals for SHSE:600613:
EV-to-FCF: 11.34 (40% below median its 10-year median of 18.91)
GF Value™: ¥5.44 vs. price of ¥4.82 (11.4% below fair value)
Industry Position: 45.6% below the Drug Manufacturers median (#143 of 563)
No single metric tells the full story. See the SHSE:600613 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Shenqi Pharmaceutical Investment Management Co Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600613 has been successfully added to your 
